EyePoint Pharmaceuticals (Nasdaq: EYPT) is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert® technology for sustained intraocular drug delivery including EYP-1901, an investigational sustained delivery intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.
Investor Relations
IR CONTACTS
Stern Investor Relations
p. 212.362.1200
e. eyepoint@sternir.com
MEDIA RELATIONS CONTACT
Amy Phillips
p. 412.327.9499
e. aphillips@greenroompr.com
Menu
EyePoint and the EyePoint logo are registered trademarks of EyePoint Pharmaceuticals, Inc.
©2021 EyePoint Pharmaceuticals, Inc. All rights reserved.
EYEPOINT, the EyePoint logo, DURASERT, and DEXYCU are registered trademarks of EyePoint Pharmaceuticals.
© EyePoint Pharmaceuticals. All rights reserved.